New Delhi : Covishield vaccines have shown a faster antibody response in people who defeated corona infection. This has raised hopes that such people will not need to be given a second dose of vaccine and thus help in expanding the coronavirus vaccination in the country.
The study on Covishield’s immune response has been done by CSIR-Institute of Genomics and Integrative Biology (IGIB), Max Super Specialty Hospital and Institute of Endocrinology, Diabetes and Metabolism as well as Academy of Scientific and Innovative Research (ACSIR) Ghaziabad, New Delhi. .
Researchers involved in the study and CSIR-IGIB director Anurag Aggarwal said that a strong immune response from Covishield has been observed. In those who are seropositive in origin, the reaction is rapid and antibodies reach high levels.
Seropositivity indicates the presence of virus in the serum or evidence that the person concerned has previously been exposed to the virus. Notably, the Covishield vaccine is a product of Oxford-AstraZeneca and is being manufactured by the Serum Institute of India, Pune.
